| Autor: |
Gasmi A; Société Francophone de Nutrithérapie et de Nutrigénétique Appliquée, 69100 Villeurbanne, France.; Research Department, Precision Health International, Ain Oulmene 19200, Algeria., Mujawdiya PK; Inochi Care Private Limited, New Delhi 110017, India., Nehaoua A; Research Department, Precision Health International, Ain Oulmene 19200, Algeria.; Laboratory of Physical Activity Sciences and Public Health, Mohamed Lamine Debaghine Sétif 2 University, Setif 19000, Algeria., Shanaida M; I. Horbachevsky Ternopil National Medical University, 46001 Ternopil, Ukraine., Semenova Y; Nazarbayev University School of Medicine, Astana 010000, Kazakhstan., Piscopo S; Department of Nutritional Research and Development, Nutri-Logics SA, 9990 Weiswampach, Luxembourg., Menzel A; Laboratoires Réunis, 6131 Junglinster, Luxembourg., Voloshyn V; I. Horbachevsky Ternopil National Medical University, 46001 Ternopil, Ukraine., Voloshyn O; Ternopil Volodymyr Hnatiuk National Pedagogical University, 46027 Ternopil, Ukraine., Shanaida V; Ternopil Ivan Puluj National Technical University, 46001 Ternopil, Ukraine., Bjørklund G; Council for Nutritional and Environmental Medicine (CONEM), 8610 Mo i Rana, Norway. |
| Abstrakt: |
The obesity pandemic is one of society's most urgent public health concerns. One-third of the global adult population may fall under obese or overweight by 2025, suggesting a rising demand for medical care and an exorbitant cost of healthcare expenditure in the coming years. Generally, the treatment strategy for obese patients is largely patient-centric and needs dietary, behavioral, pharmacological, and sometimes even surgical interventions. Given that obesity cases are rising in adults and children and lifestyle modifications have failed to produce the desired results, the need for medical therapy adjunct to lifestyle modifications is vital for better managing obesity. Most existing or past drugs for obesity treatment target satiety or monoamine pathways and induce a feeling of fullness in patients, while drugs such as orlistat are targeted against intestinal lipases. However, many medications targeted against neurotransmitters showed adverse events in patients, thus being withdrawn from the market. Alternatively, the combination of some drugs has been successfully tested in obesity management. However, the demand for novel, safer, and more efficacious pharmaceutical medicines for weight management does exist. The present review elucidates the current understanding of the available anti-obesity medicines of synthetic and natural origin, their main mechanisms of action, and the shortcomings associated with current weight management drugs. |
